Jyong Biotech Ltd. (MENS)
Nasdaq · Healthcare · Biotechnology
$2.05−5.96%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $156M
- 52-week range
- $1.43 – $63.00
- 52-week change
- −96.04%
- EPS (trailing)
- −$0.06
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$4.7M
- Diluted EPS
- −$0.06
From the company’s annual report on SEC EDGAR.
About Jyong Biotech Ltd.
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Headquarters: New Taipei City, Taiwan · 27 employees · jyongbio.com